Roche’s megablockbuster MS candidate ocrelizumab posts promising head-to-head data
By most accounts, Roche’s ocrelizumab is likely the biggest drug in the industry’s late-stage pipeline, with peak revenue potential ranging up to a megablockbuster …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
